Wells Fargo 2026 MedTech Innovation Spotlight
Logotype for Inspire Medical Systems Inc

Inspire Medical Systems (INSP) Wells Fargo 2026 MedTech Innovation Spotlight summary

Event summary combining transcript, slides, and related documents.

Logotype for Inspire Medical Systems Inc

Wells Fargo 2026 MedTech Innovation Spotlight summary

26 Jun, 2026

Coding and reimbursement updates

  • Clear coding pathways established for Medicare, commercial, and Medicare Advantage, with ongoing education for centers and physicians to ensure reimbursement confidence.

  • Payment levels for facilities and physicians remain consistent with 2025, with minor variations due to modifiers.

  • Two of seven Medicare MACs require a -52 modifier, resulting in a 10%-20% reduction in physician payment; others may follow, but tools are in place to adapt.

  • A new CPT code application was submitted to the AMA for review in September 2026, aiming for implementation by January 2028.

  • WISeR program implementation in six states is improving, with initial headwinds expected to lessen throughout the year.

Technology and product innovation

  • Inspire V system launched with closed-loop sensing, improving synchronization of stimulation to 87.1% of breaths and eliminating the need for a respiratory sensor.

  • SleepSync platform enhancements allow digital prior authorization requests, streamlining administrative processes for centers.

  • Inspire VI is in development, focusing on auto-activation and sleep detection to further improve therapy adherence.

  • Remote programming for SleepSync is under development, with no set release date yet.

Clinical evidence and outcomes

  • ADHERE registry of 5,000 patients shows median Apnea-Hypopnea Index reduction from 32 to 10 and 90% patient satisfaction.

  • Therapy adherence averages 5.8–6.4 hours per night, with most patients not requiring sleep endoscopy based on new PREDICTOR algorithm.

  • New data links Inspire therapy to significant reductions in hypoxic burden, correlating with improved cardiovascular health.

  • Large real-world studies show Inspire associated with lower risk of heart failure, coronary artery disease, and cardiomyopathy compared to CPAP and no treatment.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more